RecruitingNCT05463796
Rare condition
Giant cell tumor of bone
9
studies recruiting now
as of 7 Sept 2026
44
studies registered in total
as of 7 Sept 2026
5
countries with a recruiting site
as of 7 Sept 2026
27 May 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT06239272
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RecruitingNCT07609277
TRACP-5b for Diagnosis and Follow-up of Giant Cell Tumor of Bone
RecruitingPhase 3NCT03295981
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
RecruitingPhase 4NCT07315828
Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 9 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Giant cell tumor of bone study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Giant cell tumor of bone
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment and 1 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Denosumab (Jubbonti)
Phase 1/2Indocyanine Green (Ic-green)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).